Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues

Liver Transplantation

Volumn 19, Issue 9, 2013, Pages 1020-1029

  Campsen, Jeffrey ^a,h   Zimmerman, Michael ^b   Trotter, James ^a   Hong, Johnny ^c   Freise, Chris ^d   Brown, Robert ^e   Cameron, Andrew ^f   Ghobrial, Mark ^g   Kam, Igal ^b   Busuttil, Ronald ^c   Saab, Sammy ^c   Holt, Curtis ^c   Emond, Jean ^e   Stiles, Jessica ^e   Lukose, Thresiamma ^e   Chang, Matthew ^e   Klintmalm, Goran ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g HOUSTON METHODIST HOSPITAL   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CHLOROTRIANISENE; ENTECAVIR; HEPATITIS B ANTIBODY; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PRIORITY JOURNAL; REINFECTION; RETROSPECTIVE STUDY; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; FEMALE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOSIDES; NUCLEOTIDES; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84883245995     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23703     Document Type: Article

References (35)

1. Huang MA, Lok AS,. Natural history of hepatitis B and outcomes after liver transplantation. Clin Liver Dis 2003; 7: 521-536.
2. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER,. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-974.
3. Llovet JM, Schwartz M, Mazzaferro V., Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
4. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619.
5. Island ER, Pomposelli J, Pomfret EA, Gordon FD, Lewis WD, Jenkins RL,. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 2005; 140: 353-358.
6. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
7. Molmenti EP, Klintmalm GB,. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8: 736-748.
8. Roche B, Samuel D,. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10 (suppl 2): S74-S85.
9. Roche B, Samuel D,. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 2005; 17: 746-758.
10. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M,. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-655.
11. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al.; for Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
12. Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708-2716.
13. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
14. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ,. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434-439.
15. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182-187.
16. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
17. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al.; for Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
18. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-224.
19. Zhang J, Zhou L, Zheng SS,. Clinical management of hepatitis B virus infection correlated with liver transplantation. Hepatobiliary Pancreat Dis Int 2010; 9: 15-21.
20. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M,. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
21. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-1899.
22. Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, et al. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008; 40: 1511-1517.
23. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with hepatitis C. Liver Transpl 2004; 10: 1478-1486.
24. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW,. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280.
25. Campsen J., Multicenter review of liver transplant for hepatitis B related liver disease: disparities in gender and ethnicity. Liver Transpl. In press.
26. Roayaie S, Haim MB, Emre S, Fishbein TM, Sheiner PA, Miller CM, Schwartz ME,. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Western experience. Ann Surg Oncol 2000; 7: 764-770.
27. Liver (including intrahepatic bile ducts). In:, Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002: 131-138.
28. Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, et al.; for NIH HBV OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011; 25: E152-E162.
29. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190.
30. Holman M, Harrison D, Stewart A, Stone M, Goldstein R, Husberg B, Klintmalm G,. Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. N J Med 1995; 92: 519-522.
31. Roberts JP,. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005; 11 (suppl 2): S45-S46.
32. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534.
33. Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511-517.
34. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
35. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB,. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011; 17 (suppl 2): S81-S89.